SALT LAKE CITY, UTAH (PRWEB) JULY 17, 2017 Salt Lake City, UT – July 17, 2017 – Co-Diagnostics, Inc. (NASDAQ:
Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has developed and intends to manufacture
Following a visit to Eureka Medical Laboratories (EML) in Georgetown, Guyana, EML was featured in an article in the
Co-Diagnostics received a mention from a local news outlet for being on the front lines of the war on Zika.
Co-Diagnostics CEO Dwight Egan is currently visiting the countries of Guyana and Trinidad and Tobago, where he has been
We are happy to announce that earlier this month the company received notification that our patent titled “Nucleic Acid
As news of our work on Zika virus continues to generate interest, another story was recorded and aired yesterday. This coverage
Following our recent press release, the local NBC affiliate station spent some time in our lab to discuss the efforts
See original release on PRWeb. SANDY, UT (PRWEB) FEBRUARY 04, 2016 Co-Diagnostics, Inc. announced today that the company has
On January 14th, the company received official certificates for ISO 13485 : 2003 and ISO 9001 : 2008, with
View Release on PRWeb Co-Diagnostics CEO to present at 2015 SALSS in Stockholm, Sweden SANDY, UT (PRWEB) AUGUST 20,
Dear Co-Diagnostics shareholders, supporters, and followers, It is estimated that nearly 9 million people worldwide contract tuberculosis each year.
We are pleased to announce that Co-Diagnostics’ real-time PCR test for malaria, built on our patent-pending CoPrimers™ technology, is ready for
Dear shareholders and customers of Co-Diagnostics, We are pleased to announce that on December 31, 2014, the Management of
Dear Co-Diagnostics shareholders, We are excited to announce that we have received our official certificates for ISO 13485, the